Natali Rodriguez Peñaranda, Francesco di Bello, Andrea Marmiroli, Fabian Falkenbach, Mattia Longoni, Quynh Chi Le, Jordan A Goyal, Zhe Tian, Fred Saad, Shahrokh F Shariat, Nicola Longo, Ottavio de Cobelli, Markus Graefen, Alberto Briganti, Felix K H Chun, Giuseppe Stella, Adele Piro, Stefano Puliatti, Salvatore Micali, Pierre I Karakiewicz
{"title":"Urinary Diversion Versus Adverse In-Hospital Outcomes After Radical Cystectomy.","authors":"Natali Rodriguez Peñaranda, Francesco di Bello, Andrea Marmiroli, Fabian Falkenbach, Mattia Longoni, Quynh Chi Le, Jordan A Goyal, Zhe Tian, Fred Saad, Shahrokh F Shariat, Nicola Longo, Ottavio de Cobelli, Markus Graefen, Alberto Briganti, Felix K H Chun, Giuseppe Stella, Adele Piro, Stefano Puliatti, Salvatore Micali, Pierre I Karakiewicz","doi":"10.1245/s10434-024-16644-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare adverse in-hospital outcomes in ileal conduit versus neobladder urinary diversion type after radical cystectomy (RC) in contemporary versus historical patients.</p><p><strong>Methods: </strong>Patients were identified within the National Inpatient Sample (NIS 2000-2019). Propensity score matching (PSM; 1:2 ratio) and multivariable logistic regression models (LRMs) were used.</p><p><strong>Results: </strong>Of 10,533 contemporary (2011-2019) patients, 943 (9.0%) underwent neobladder urinary diversion, while 9590 (91.0%) underwent ileal conduit urinary diversion. Furthermore, of 9742 historical (2010-2019) patients, 932 (9.6%) underwent neobladder urinary diversion and 8810 (90.4%) underwent ileal conduit urinary diversion. After 1:2 PSM, within the contemporary cohort, 943/943 (100%) neobladder versus 1886/9590 (19.6%) ileal conduit patients were included. Similarly, within the historical cohort, 932/932 (100%) neobladder versus 1864/8810 (21.1%) ileal conduit patients were included after PSM. In multivariable LRMs, relative to contemporary neobladder patients, contemporary ileal conduit patients exhibited higher rates of overall postoperative (49.0 vs. 43.6%; multivariable odds ratio [MOR] 1.2), wound (4.2 vs. 2.7%; MOR 1.6), and genitourinary (13.1% vs. 10.0%; MOR 1.3) complications as well as blood transfusions (19.0 vs. 15.6%; MOR 1.3). Conversely, in multivariable LRMs within the historical cohort, no differences were recorded between ileal conduit and neobladder patients.</p><p><strong>Conclusions: </strong>Unlike historical comparisons between ileal conduit and neobladder patients, where no differences in adverse in-hospital outcomes were recorded, analyses relying on a contemporary patient cohort subject to PSM and multivariable adjustment revealed higher rates of adverse in-hospital outcomes in 4/13 examined categories. This observation should be considered at informed consent.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"2233-2240"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-024-16644-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to compare adverse in-hospital outcomes in ileal conduit versus neobladder urinary diversion type after radical cystectomy (RC) in contemporary versus historical patients.
Methods: Patients were identified within the National Inpatient Sample (NIS 2000-2019). Propensity score matching (PSM; 1:2 ratio) and multivariable logistic regression models (LRMs) were used.
Results: Of 10,533 contemporary (2011-2019) patients, 943 (9.0%) underwent neobladder urinary diversion, while 9590 (91.0%) underwent ileal conduit urinary diversion. Furthermore, of 9742 historical (2010-2019) patients, 932 (9.6%) underwent neobladder urinary diversion and 8810 (90.4%) underwent ileal conduit urinary diversion. After 1:2 PSM, within the contemporary cohort, 943/943 (100%) neobladder versus 1886/9590 (19.6%) ileal conduit patients were included. Similarly, within the historical cohort, 932/932 (100%) neobladder versus 1864/8810 (21.1%) ileal conduit patients were included after PSM. In multivariable LRMs, relative to contemporary neobladder patients, contemporary ileal conduit patients exhibited higher rates of overall postoperative (49.0 vs. 43.6%; multivariable odds ratio [MOR] 1.2), wound (4.2 vs. 2.7%; MOR 1.6), and genitourinary (13.1% vs. 10.0%; MOR 1.3) complications as well as blood transfusions (19.0 vs. 15.6%; MOR 1.3). Conversely, in multivariable LRMs within the historical cohort, no differences were recorded between ileal conduit and neobladder patients.
Conclusions: Unlike historical comparisons between ileal conduit and neobladder patients, where no differences in adverse in-hospital outcomes were recorded, analyses relying on a contemporary patient cohort subject to PSM and multivariable adjustment revealed higher rates of adverse in-hospital outcomes in 4/13 examined categories. This observation should be considered at informed consent.
目的:本研究旨在比较当代和历史患者根治性膀胱切除术(RC)后回肠导管和新膀胱尿转移类型的不良住院结果。方法:在国家住院患者样本(NIS 2000-2019)中确定患者。倾向得分匹配(PSM;1:2比例)和多变量logistic回归模型(lrm)。结果:在当代10533例(2011-2019)患者中,943例(9.0%)行新膀胱尿分流,9590例(91.0%)行回肠导管尿分流。此外,在9742例历史(2010-2019)患者中,932例(9.6%)接受了新膀胱尿转移,8810例(90.4%)接受了回肠导管尿转移。在1:2 PSM后,在当代队列中,943/943例(100%)新膀胱患者和1896 /9590例(19.6%)回肠导管患者被纳入。同样,在历史队列中,PSM后纳入了932/932例(100%)新膀胱患者和1864/8810例(21.1%)回肠导管患者。在多变量lrm中,相对于当代新膀胱患者,当代回肠导管患者的总体术后发生率更高(49.0% vs 43.6%;多变量优势比[MOR] 1.2),伤口(4.2 vs. 2.7%;MOR 1.6),泌尿生殖系统(13.1% vs. 10.0%;MOR 1.3)并发症和输血(19.0% vs. 15.6%;铁道部1.3)。相反,在历史队列中的多变量lrm中,回肠导管和新膀胱患者之间没有记录差异。结论:与回肠导管和新膀胱患者之间的历史比较不同,其中没有记录到不良住院结局的差异,依赖于接受PSM的当代患者队列和多变量调整的分析显示,在4/13个检查类别中,不良住院结局的发生率更高。这一意见应在知情同意时予以考虑。
期刊介绍:
The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.